495
edits
EVOLVE: Difference between revisions
Jump to navigation
Jump to search
→KDIGO CKD-BMD Guidelines 2009
Michaelw2000 (talk | contribs) Tag: visualeditor |
Michaelw2000 (talk | contribs) Tag: visualeditor |
||
| Line 51: | Line 51: | ||
==Guidelines== | ==Guidelines== | ||
=== KDIGO CKD-BMD Guidelines 2009 === | === KDIGO CKD-BMD Guidelines 2009<ref>http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO%20CKD-MBD%20GL%20KI%20Suppl%20113.pdf</ref> === | ||
''These guidelines reflect the outcomes of the EVOLVE trial. The working group of the 2013 KDIGO Controversies Conference did not make changes to the 2009 recommendations.'' | ''These guidelines reflect the outcomes of the EVOLVE trial. The working group of the 2013 KDIGO Controversies Conference did not make changes to the 2009 recommendations.''<ref>http://www.kdigo.org/ControConf/CKD-MBD%202013/KDIGO%202013%20CKD-MBD%20Controversies%20Conf%20Report%20AOP.pdf</ref> | ||
In patients with CKD stage 5D and elevated or rising PTH, we suggest calcitriol, or vitamin D analogs, or calcimimetics, or a combination of calcimimetics and clacitriol or vitamin D analogs be used to lower PTH (2B). | In patients with CKD stage 5D and elevated or rising PTH, we suggest calcitriol, or vitamin D analogs, or calcimimetics, or a combination of calcimimetics and clacitriol or vitamin D analogs be used to lower PTH (2B). | ||
| Line 206: | Line 206: | ||
* High drop-in rates in the placebo group (use of commercial cinacalcet) | * High drop-in rates in the placebo group (use of commercial cinacalcet) | ||
* Under the initial assumption of a 20% treatment effect, the study power dropped to 54%<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983668/</ref> | * Under the initial assumption of a 20% treatment effect, the study power dropped to 54%<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983668/</ref> | ||
* Combination of atherosclerotic and non-atherosclerotic endpoints | |||
** Cinacalcet hypothesized to primarily effect non-atherosclerotic endpoints (slowing arterial calcification, reducing myocardial calcium accumulation)<ref>http://cjasn.asnjournals.org/content/2/1/89.full</ref> | |||
==Funding==<!-- remove when cleared by an editor --> | ==Funding==<!-- remove when cleared by an editor --> | ||